



March 9th, 2015

ViperGen Enters into Multi-Target Collaboration with Nurix, Inc.

Copenhagen, Denmark, March 9th, 2015 - - ViperGen ApS a biotechnology company focused on small molecule drug discovery using its proprietary 2nd generation DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Nurix, Inc. a leader in discovering innovative drugs that modulate protein function through the ubiquitin proteasome system.

Under the terms of the agreement, ViperGen is applying its small molecule discovery engine, which leverages a high fidelity proprietary DNA-encoded library platform to identify novel hits/leads for protein targets specified by Nurix. Nurix has an exclusive option to license any compounds generated in the course of the collaboration. Other terms of the agreement were not disclosed.

“We are thrilled to work with Nurix, a leader in the ubiquitin proteasome system, on targets which are difficult from a drug discovery standpoint,” said Nils Hansen, Ph.D., Chief Executive Officer of ViperGen. “ViperGen has designed and implemented its discovery engine to meet the challenges of such highly difficult targets.”

About Nurix

Nurix, Inc. is a leader in discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell through the ubiquitin proteasome system (UPS). The UPS is a regulatory pathway that controls protein stabilization and degradation, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas, including oncology and immuno-oncology. Nurix’s state-of-the-art product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field and is funded by leading life science investors, Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California. For more information, please visit www.nurix-inc.com.

About ViperGen ApS

ViperGen is dedicated to small molecule drug discovery using DNA-encoded library platforms.

ViperGen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.

ViperGen’s two 2nd generation technology platforms - The YoctoReactor[®] for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment[®] for screening of such libraries - are designed to deliver high fidelity drug discovery.

For further details about ViperGen and the YoctoReactor[®]/ Binder Trap Enrichment[®] drug discovery technology platforms please visit www.viperGen.com or contact:

ViperGen ApS

Dr. Nils Hansen, Chief Executive Officer
Phone: +45 2523 6680
nha@viperGen.com